Seaport Q1 net loss $25.4M; cash $212.6M; GlyphAgo Ph1 shows liver safety; GlyphAllo Ph2b on track

Seaport Therapeutics, Inc.

Net loss $25.4M (vs $13.1M YoY); R&D expenses $21.4M, up from $10.5M YoY.
Cash $212.6M at Q1 end; +$260M from May IPO provides runway into 2029.
GlyphAgo Phase 1 MAD data show therapeutic exposures at doses avoiding liver enzyme elevations, no liver AEs.
GlyphAllo Phase 2b BUOY-1 enrollment on track; topline data 1H 2027; driving simulation trial dosed, data 2H 2026.
Sharon Mates appointed to board; upsized IPO raised $260M gross proceeds.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Seaport Therapeutics, Inc. reported financial results for the first quarter of 2026.

Period: the first quarter of 2026
Result: reported results

Exact text from the filing

today announced financial results for the first quarter of 2026

View on SEC.gov

700 earnings releases filed in the last 30 days. Browse all earnings releases →

Seaport Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-260671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.